 Aptose Biosciences Inc. Nasdaq: APTO; TSX: APS, a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the U.S. Food and Drug Administration FDA completed its review of the companys Investigational New Drug IND application and has granted IND allowance for the initiation of a Phase 1ab clinical study of CG-806, the companys highly potent, oral FLT3BTK inhibitor, in patients with acute myeloid leukemia AML. CG-806 is currently in a Phase 1 dose escalation study in patients with B-cell malignancies, including chronic lymphocytic leukemia CLL and non-Hodgkins lymphomas NHL, who have failed or are intolerant to current therapies. 